Third-trimester bleeding is a common complication arising from a variety of etiologies, some of which may initially present in the late preterm period. Previous management recommendations have not been specific to this gestational age window, which carries a potentially lower threshold for delivery. The purpose of this document is to provide guidance on management of late preterm (34 0/7–36 6/7 weeks of gestation) vaginal bleeding. The following are Society for Maternal-Fetal Medicine recommendations: (1) we recommend delivery at 36–37 6/7 weeks of gestation for stable women with placenta previa without bleeding or other obstetric complications (GRADE 1B); (2) we do not recommend routine cervical length screening for women with placenta previa in the late preterm period due to a lack of data on an appropriate management strategy (GRADE 2C); (3) we recommend delivery between 34 and 37 weeks of gestation for stable women with placenta accreta (GRADE 1B); (4) we recommend delivery between 34 and 37 weeks of gestation for stable women with vasa previa (GRADE 1B); (5) we recommend that in women with active hemorrhage in the late preterm period, delivery should not be delayed for the purpose of administering antenatal corticosteroids (GRADE 1B); (6) we recommend that fetal lung maturity testing should not be used to guide management in the late preterm period when an indication for delivery is present (GRADE 1B); and (7) we recommend that antenatal corticosteroids should be administered to women who are eligible and are managed expectantly if delivery is likely within 7 days, the gestational age is between 34 0/7 and 36 6/7 weeks of gestation, and antenatal corticosteroids have not previously been administered (GRADE 1A).

Key words: late preterm bleeding, late preterm delivery, late preterm vaginal bleeding, placenta accreta, placental abruption, placenta previa, vasa previa

What are the etiologies of late preterm antepartum third-trimester bleeding?
The phrase, third-trimester bleeding, defines vaginal blood loss that occurs in the latter part of pregnancy and can range from spotting to obstetric hemorrhage. There is no universally agreed-upon definition of antepartum obstetric hemorrhage; however, the definition most frequently used is bleeding from the genital tract that occurs in the latter half of gestation.

The etiologies of third-trimester bleeding are varied and of differing acuity. The epidemiology of late preterm vaginal bleeding has not previously been described. Although bleeding during this time is usually attributed to placenta previa, placental abruption, or vasa previa, there are other causes of bleeding that occurs late in pregnancy. Lesions of the lower genital tract or early labor are common etiologies of late pregnancy bleeding. Etiologies of late preterm bleeding are listed in Table 1.

Etiologies of late preterm bleeding

Placenta previa
Placenta previa can cause late preterm third-trimester bleeding and is defined as placental implantation that...
overlies or abuts the internal cervical os. Classically, a patient presents with painless bleeding. Diagnosis is most accurately made by transvaginal ultrasound. The incidence of placenta previa ranges from 5% to 20% with second-trimester transabdominal ultrasonography. Transvaginal ultrasound provides a more accurate diagnosis than transabdominal ultrasound, with estimates of prevalence in the second trimester of 1–4%. The prevalence of placenta previa decreases to 0.3–0.5% at term. Risk factors for placenta previa include advanced maternal age, multiparity, prior cesarean delivery, multifetal gestation, and smoking.

Recommendations for timing of delivery in a woman who presents with placenta previa vary, based on the amount of bleeding and maternal and fetal status. We recommend delivery at 36–37 6/7 weeks of gestation for stable women with placenta previa without bleeding or other obstetric complications, (GRADE 1B).

Women with active, ongoing obstetric hemorrhage in the late preterm period, regardless of etiology, require stabilization and preparation for delivery. Similarly, because the likelihood of a subsequent bleeding episode increases with the number of prior bleeding episodes as well as with increasing gestational age, delivery may be considered for women presenting with mild to late preterm bleeding who have had 1 or more prior bleeding episodes at less than 34 weeks of gestation.

The management of women with initial mild bleeding episodes at 34–35 weeks of gestation that has resolved by the time of evaluation is less clear. Several small studies suggest that cervical length measurement may help distinguish those who are likely to have another bleed from those who are not likely to bleed again. However, we do not recommend routine cervical length screening for women with placenta previa in the late preterm period due to a lack of data on an appropriate management strategy (GRADE 2C).

**Placenta accreta**

Placenta accreta is defined as abnormal trophoblast infiltration beyond the fibrinoid Nitabuch layer, resulting in abnormal adherence to the myometrium. If the placenta invades the myometrium, it is termed placenta increta. If it penetrates beyond the myometrium, it is called placenta percreta.

Placenta accreta is most commonly associated with placenta previa and previous cesarean delivery; other risk factors include previous uterine surgery, advanced maternal age, smoking, and multiparity. The incidence of accreta in the absence of placenta previa is <1% unless a woman has had more than 5 prior cesareans.

Antepartum bleeding risk with placenta accreta is primarily related to the common occurrence of coexisting placenta previa. In general, women with placenta accreta are at greatest risk of bleeding at the time of delivery.

Diagnosis is generally made by ultrasonography, and sonographic markers suggestive of placenta accreta have been described. These include multiple vascular lacunae within the placenta, blood vessels traversing the uteroplacental or uterovesicular junctions, loss of the normal hypoechoic retroplacental zone, a retroplacental myometrial thickness of <1 mm, or numerous coherent vessels visualized with 3-dimensional power Doppler in the basal view.

Delivery timing for stable women with placenta accreta is based on the severe maternal morbidity associated with emergent bleeding. Warshak et al describe outcomes for cases of placenta accreta in which the diagnosis was made before delivery. Four of 9 cases of antenatally suspected placenta accreta managed beyond 36 weeks of gestation (44.4%) required emergent delivery for hemorrhage. A decision analysis to identify the most appropriate delivery timing for women with accreta, taking into account maternal and neonatal morbidities, concluded that 34 weeks was the ideal gestational age for delivery.

Risk factors for unscheduled preterm delivery in this population include vaginal bleeding and the presence of uterine contractions, with each episode of bleeding increasing the likelihood of unscheduled delivery. Based on this and other data, we recommend delivery between 34 and 37 weeks of gestation for stable women with placenta accreta (GRADE 1B).

Delivery is indicated for women with placenta accreta and late preterm bleeding; however, for women who are clinically stable, delivery can be delayed briefly to coordinate logistics and assemble the care team.

**Table 1**

<table>
<thead>
<tr>
<th>Obstetric</th>
<th>Nonobstetric</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placenta previa</td>
<td>Internal or external hemorrhoids</td>
</tr>
<tr>
<td>Placenta accreta, increta, or percreta</td>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>Placental abruption</td>
<td>Bladder or kidney stones</td>
</tr>
<tr>
<td>Vasa previa</td>
<td>Lower gastrointestinal bleeding</td>
</tr>
<tr>
<td>Early labor</td>
<td>Lower genital tract lesions</td>
</tr>
</tbody>
</table>

The diagnosis of abruption is best made by history and clinical presentation. Ultrasonography fails to detect placental abruption in approximately 20–50% of cases. One series reports a 24% specificity, with a 53% negative predictive value for ultrasonographic diagnosis of abruption. Because a small proportion of women with abruption present without vaginal bleeding, this diagnosis should be considered when in women who present with nonreassuring fetal status and uterine irritability on tocology. Often, abruption is a diagnosis of exclusion in a woman with vaginal bleeding and no other identified etiology.

There are no clinical trials to guide timing of delivery for women with preterm abruption. Expert opinion suggests that delivery timing of stable women with a high clinical index of suspicion for a placental abruption should be in the late preterm or early term period. If the diagnosis is unclear, bleeding is minimal, and the maternal and fetal status remain stable, delivery may be delayed with close surveillance and ongoing fetal testing. However, as with other women presenting with active hemorrhage from any etiology in the late preterm period, delivery is indicated in the setting of abruption with significant vaginal bleeding, abnormal laboratory results including acute anemia or coagulopathy, abnormality of the fetal heart tracing, or maternal instability.

**Vasa previa**

Vasa previa, an uncommon but potentially devastating condition that complicates approximately 1 in 2500 pregnancies, occurs when fetal vessels course through the membranes and traverse the internal os. Vasa previa should be suspected in cases of velamentous cord insertion, after resolved placenta previa or with a known succenturiate lobe. Other risk factors for vasa previa include in vitro fertilization and multiple gestation.

Perinatal morbidity and mortality associated with vasa previa are related to fetal vessel disruption at the time of membrane rupture. Older literature reports up to a 60% perinatal mortality with this diagnosis. However, these rates vary with prenatal diagnosis. In 1 case series, antenatal diagnosis of vasa previa was associated with a 97% survival rate compared with a 44% survival rate without prenatal diagnosis. As a result of recommendations to evaluate the placenta and placental cord insertion at the time of second-trimester ultrasound, antenatal diagnosis is now more common.

Recommendations about timing of delivery for vasa previa are primarily directed at care for women with antenatal diagnoses who are stable. Because of the potential devastating effects of fetal vessel rupture, as well as the increasing likelihood of spontaneous labor, we recommend delivery between 34 and 37 weeks of gestation for stable women with vasa previa (GRADE 1B). Emergent delivery is indicated for any woman with late preterm bleeding because of known vasa previa.

**What is the evaluation of women who present with late preterm bleeding?**

A detailed history and physical examination are important in the evaluation of bleeding in the late preterm period. Pertinent elements in the history include the amount and duration of bleeding as well as a review of the woman’s obstetric course, including any prior bleeding.

A history of cesarean delivery, myomectomy, or dilation and curettage is important because these are thought to increase the risk of placenta accreta. Imaging results should be reviewed to evaluate reported placentation. A review of the chart may also reveal previously noted cervicovaginal pathology that may contribute to bleeding, such as ectropion or cervical polyps. However, because the woman’s diagnosis can evolve over time, chart review should not be a substitute for the bedside patient evaluation, including ultrasound evaluation.

The physical examination should include an assessment of both maternal and fetal status. Fetal status should be evaluated by electronic fetal monitoring. A speculum examination may be helpful to evaluate the extent and location of current bleeding. Ultrasound evaluation of placental location to rule out vasa or placenta previa should be performed prior to attempting a digital examination, particularly if placental location has not been documented or is unknown. In such cases, if ultrasound is not available, a digital vaginal examination should be avoided and other clinical findings, including the fetal heart tracing, should be used to guide further management until an ultrasound examination can be performed.

**Ultrasonography**

Ultrasonography is the most appropriate imaging modality to recognize or exclude placenta previa or vasa previa as the cause of late preterm vaginal bleeding. Specifically, transvaginal ultrasound should be performed to evaluate for placenta previa because the safety and reliability of this approach have been shown.

To confirm the diagnosis of vasa previa, pulsed-wave Doppler can be used to identify an arterial vessel with a fetal heart rate, although the presence of fetal vessels with venous blood flow identified with color Doppler may be equally ominous.

As described above, ultrasound evaluation is also useful in the diagnosis of placenta accreta, but the sensitivity (89–92%) and specificity (92–97%) for diagnosis are lower than for placenta previa or vasa previa. Placental abruption is easily missed by ultrasound; therefore, a high clinical suspicion for abruption should dictate management. Because the role of magnetic resonance imaging in the assessment of placenta accreta remains unclear, this modality is not routinely recommended for the evaluation of a woman presenting with acute bleeding at 34–36 weeks of gestation.
Laboratory evaluation

The laboratory evaluation for late preterm bleeding depends on the degree of bleeding and the woman’s clinical status and can include a complete blood count with platelets, a type and crossmatch, prothrombin time/ and partial prothrombin time-International Normalized Ratio (INR) to evaluate coagulation factors, and fibrinogen. Blood urea nitrogen, creatinine, and electrolytes may also be assessed if the likelihood for transfusion is high.

A wall clot is a useful test to assess coagulopathy with acute bleeding. To perform this test, blood is placed into a plain (red-top) tube and put aside. The blood should clot within 6 minutes, and delayed clotting beyond this time is suggestive of coagulopathy.50

In women who are Rh negative, a quantitative rosette test, a qualitative Kleihauer-Betke stain, or flow cytometry may be useful to determine the degree of fetal-maternal hemorrhage.51 A standard Rh immunoglobulin dose of 300 μg should be administered to patients with bleeding who are Rh negative, unless the Kleihauer-Betke stain suggests that additional doses of Rh immunoglobulin are needed.52 Kleihauer-Betke testing is not indicated for women with late preterm bleeding unless they are Rh negative.53

What is the management for women with late preterm bleeding?

Timing of delivery

The management of women presenting with late preterm bleeding depends on the amount and duration of bleeding, maternal and fetal status, presence of preterm labor or ruptured membranes, and the patient’s proximity to the hospital. The decision for delivery is highly dependent on the degree and etiology of bleeding.

Stabilization and preparation for delivery is indicated in women with an active, ongoing hemorrhage in the late preterm period, regardless of etiology. Stabilization includes the placement of 2 large-bore intravenous lines, determination of blood type and cross-matching for an initial 2–4 U of blood, and laboratory evaluation as described previously.

Fetal heart rate monitoring is also indicated. Many labor units utilize obstetric hemorrhage bundles or massive transfusion protocols; these tools should be used in women with acute hemorrhage as appropriate.54,55 Many successful management strategies involve a multidisciplinary approach that includes the obstetric, nursing, and anesthesia teams. Assembling this team will allow for simultaneous efforts including initial resuscitation by fluid, blood, and blood products; alerting the blood bank to the possibility of massive hemorrhage; identifying and prepping O-negative blood while the woman is cross-matched; and preparing the operating room.

Mode of delivery will vary by clinical circumstances; women with an accreta or placenta previa will be delivered by cesarean, while women without a contraindication for vaginal delivery and reassuring fetal status are candidates for vaginal delivery. We recommend that in women with active hemorrhage in the late preterm period, delivery should not be delayed for the purpose of administering antenatal corticosteroids (ACS) (GRADE 1B).56 We also recommend that fetal lung maturity testing should not be used to guide management in the late preterm period when an indication for delivery is present (GRADE 1B).57 Maturation of the fetal lungs does not confirm maturation of other organ systems. A summary of indications for delivery is listed in Table 2.

Indications for expectant management

There are no current evidence-based recommendations for women who have a small amount of late preterm bleeding that has resolved by presentation to care. The conditions suggesting expectant management include maternal hemodynamic stability, reassuring fetal status, absence of active bleeding or contractions, and proximity of the patient to the hospital. Bleeding from ectropion, cervical polyps, or early labor is generally minor and self-limited. In the

### TABLE 2

Late preterm delivery timing by etiology of bleeding

<table>
<thead>
<tr>
<th>Etiology of hemorrhage</th>
<th>Amount of bleeding</th>
<th>Delivery</th>
<th>Expectant management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placenta previa</td>
<td>Heavy</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Light</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasa previa</td>
<td>Any</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Placenta accreta</td>
<td>Any</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Placental abruption</td>
<td>Depends on index of suspicion and amount of bleeding</td>
<td>+ (if high index of suspicion and/or heavy bleeding)</td>
<td>+ (if low index of suspicion and light bleeding)</td>
</tr>
<tr>
<td>Cervicovaginal lesions (ectropion, cervical polyp, etc)</td>
<td>Any</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

We recommend that ACS should be administered to women who are eligible and are planned to be managed expectantly if delivery is likely within 7 days, the gestational age is between 34 0/7 and 36 6/7 weeks of gestation, and if ACS have not previously been administered (GRADE 1A).  

Similarly, women with placenta previa and a subjectively small bleed that has resolved by presentation may be observed and managed expectantly if this represents the first bleed in the pregnancy. Consideration may be given to an initial period of observation in the hospital for 24–48 hours after a subjectively heavy bleeding episode that has resolved, particularly if the etiology of the bleed is unclear.

We recommend that ACS should be administered to women who are eligible and are planned to be managed expectantly if delivery is likely within 7 days, the gestational age is between 34 0/7 and 36 6/7 weeks of gestation, and if ACS have not previously been administered (GRADE 1A).

What are the neonatal sequelae of late preterm delivery?
The rate of late preterm delivery, defined as delivery between 34 0/7 weeks through 36 6/7 weeks of gestation, has declined consistently in the United States over the past several years. Nevertheless, many indications for late preterm birth exist. Guidance about appropriate indications for late preterm delivery is available but is based mainly on expert opinion. Furthermore, this guidance does not address management decisions in the face of the expected changes in clinical status that occur in many obstetric complications.

Neonatal consequences of late preterm delivery are now well described. Infants born between 34 0/7 weeks and 36 6/7 weeks of gestation are at increased risk for neonatal respiratory morbidity compared with birth at term (≥37 weeks 0 days). The most notable respiratory morbidities for this group include respiratory distress syndrome and transient tachypnea of the newborn because pulmonary maturation continues through the late preterm period into early childhood.

Late preterm infants also have increased risks for hypoglycemia, jaundice, hyperbilirubinemia, and feeding difficulties. A recent study by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network found that administration of ACS to this group decreases some short- and long-term respiratory morbidities, such as pulmonary immaturity, respiratory distress syndrome, and transient tachypnea of the newborn.

The rate of late preterm delivery is likely within 7 days, the gestational age is between 34 0/7 and 36 6/7 weeks of gestation, and if ACS have not previously been administered (GRADE 1A).
bronchopulmonary dysplasia, and decreases the likelihood of a prolonged special care nursery stay.57 Nonetheless, in the setting of late preterm obstetric bleeding, the risks of late preterm delivery should be reviewed in the context of the potential maternal and fetal risks of continued pregnancy and possible further hemorrhage.

**What are the gaps in knowledge regarding late preterm bleeding?**

The likelihood of the recurrence of bleeding that first presents in the late preterm period is ill defined. Rather, data on recurrence of bleeding are extrapolated from the likelihood to enter spontaneous labor, which would precipitate further bleeding from many of the conditions described. Diagnostic criteria that reliably predict placental abruption are needed. Placental abruption is often a diagnosis of exclusion when other known sources of vaginal bleeding, such as placenta previa and placenta accreta, are ruled out. Finally, further epidemiological, observational, and clinical trials would be helpful to describe the incidence, interventions, and outcomes related to late preterm bleeding.

**REFERENCES**

The authors report no conflict of interest.

All authors and committee members have filed a conflict of interest disclosure delineating personal, professional, and/or business interests that might be perceived as a real or potential conflict of interest in relation to this publication. Any conflicts have been resolved through a process approved by the Executive Board.

The Society for Maternal-Fetal Medicine has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

This document has undergone an internal peer review through a multilevel committee process within the Society for Maternal-Fetal Medicine (SMFM). This review involves critique and feedback from the SMFM Publications and Document Review Committees and final approval by the SMFM Executive Committee. SMFM accepts sole responsibility for document content. SMFM publications do not undergo editorial and peer review by the American Journal of Obstetrics & Gynecology. The SMFM Publications Committee reviews publications every 18-24 months and issues updates as needed. Further details regarding SMFM Publications can be found at www.smfm.org/publications.

All questions or comments regarding the document should be referred to the SMFM Publications Committee at pubs@smfm.org.